Cell/Gene Therapy Pay Models Face Reporting, Policy Barriers

Emerging cell and gene therapy oncology treatments are well suited to value-based payment arrangements, but new contracting models must be able to contend with a complex regulatory and financial environment, experts say.

A new generation of oncology treatments that can cure specific cancers offer a potential breakthrough. Patients who would have had to struggle through chemotherapy and still faced long odds now have the chance to make a significant recovery with one or two rounds of treatment. However, these treatments are extraordinarily expensive — some can cost tens of thousands of dollars for a single course of treatment.

“Because they’re typically only administered once, that single administration has a high associated cost that’s not spread out over time,” explained Jay Jackson, a principal at Avalere Health, during a June 29 podcast.

© 2023 MMIT
Peter Johnson

Peter Johnson

Peter has been a reporter for nearly a decade. Before joining AIS Health, Peter covered a wide variety of topics in his hometown of Seattle, where he continues to live. Peter’s work has appeared in publications including The Atlantic and The Stranger. Peter attended Colby College.

Related Posts

pills-in-hands
June 8

Buprenorphine Coverage Is Improving, but Access Barriers Remain

READ MORE
a-businessman-touching-tablet-screen
June 8

CVS Exec Says Employers ‘Shape the Economics’ of PBMs

READ MORE
an-old-lady-at-the-pharmacy
June 8

Community Pharmacist Group Greets Optum Rx Programs With Cautious Optimism

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today